A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression (MEST)

March 21, 2018 updated by: Professor Tim Dalgleish, Medical Research Council
Depression involves the tendency to recall overgeneral personal memories, a phenomenon which has been linked to numerous adverse psychological outcomes. The purpose of this study is to investigate whether a group-based Memory Specificity Training (MEST) programme improves outcomes in depression, and how this compares to an education and support control group. The primary aim is to examine whether MEST, which involves repeated practice retrieving specific autobiographical memories reduces depressive symptoms immediately post-treatment, and whether this is maintained 3 months after treatment. The secondary objective of this trial is to examine the role of hypothesised cognitive processes (ie., rumination, executive control, cognitive avoidance) which may underlie improvements in depression and memory.

Study Overview

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sydney, Australia, 2022
        • Aliza Werner-Seidler

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Principal diagnosis of Major Depressive Disorder
  • History of more than one previous depressive episode
  • Current diagnosis of a Major Depressive Episode
  • Depressive symptoms rated in the mild-severe range (> 13 on the BDI-II)
  • Memory specificity < .70 (as assessed on the AMT)

Exclusion Criteria:

  • Head trauma
  • Organic brain damage
  • Secondary diagnosis of another affective disorder
  • Psychosis
  • Current drug or alcohol abuse or dependence
  • A diagnosed Axis II disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Memory Specificity Training
Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
Active Comparator: Education and Support
Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in depressive symptoms on the Beck Depression Inventory II (BDI-II)
Time Frame: Change from baseline to 3 months post-treatment
Symptom severity score
Change from baseline to 3 months post-treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in depressive status according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders - IV (SCID-IV)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment, and 6-months post-treatment (6-month follow-up for MEST group only)
Presence of a current Major Depressive Episode (MDE)
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment, and 6-months post-treatment (6-month follow-up for MEST group only)
Change from baseline in autobiographical memory specificity on Autobiographical Memory Test (AMT)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Memory specificity level
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change from baseline in depressive symptoms as measured on the BDI-II
Time Frame: Change from baseline to post-treatment (approximately 6-weeks)
Symptom severity score
Change from baseline to post-treatment (approximately 6-weeks)
Depression free days following treatment according to the Longitudinal Follow-up Evaluation on the SCID-IV
Time Frame: Post-treatment and 3-month and 6-month follow-up
Number of depression-free days
Post-treatment and 3-month and 6-month follow-up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline on the Beck Anxiety Inventory (BAI)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Symptom severity score
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change from baseline on the Beck Hopelessness Scale (BHS)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Hopelessness score
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change from baseline on the Cognitive Avoidance Questionnaire (CAQ)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Tendency for avoidance score
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change in baseline on Rumination Response Scale (RRS)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Tendency to ruminate score
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change from baseline in performance on Means-Ends Problem Solving Task (MEPS)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Problem solving effectiveness score
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change from baseline in performance on Verbal Fluency Task
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Index of executive control
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Change in baseline on performance on Digit Span Task
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
Working memory index
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Tim Dalgleish, PhD, Medical Research Council

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (Actual)

August 1, 2016

Study Completion (Actual)

October 1, 2016

Study Registration Dates

First Submitted

June 18, 2013

First Submitted That Met QC Criteria

June 18, 2013

First Posted (Estimate)

June 20, 2013

Study Record Updates

Last Update Posted (Actual)

March 22, 2018

Last Update Submitted That Met QC Criteria

March 21, 2018

Last Verified

March 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depressive Symptoms

Clinical Trials on Memory Specificity Training

3
Subscribe